Introduction: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. It is often associated with coronary and/or cerebral vascular involvement, leading to a higher risk of cardiovascular and cerebrovascular events, among which myocardial infarction, stroke and death. Cardiovascular prevention has proven effective in reducing the progression of the disease and early diagnosis leads to more rapid initiation of medical therapy. However, revascularization of the diseased segment represents the only solution in the manifest and symptomatic forms of the disease.
Areas Covered: Surgical treatment has historically represented the first treatment of PAD, which consists in the creation of bypasses excluding the obstructed segment. Nowadays, endovascular treatment represents in many cases the first line of intervention. Drug-coated balloons are a cornerstone solution for the treatment of peripheral lesions, and are supported by multiple trials demonstrating their efficacy and safety.
Expert Opinion: New devices, such as sirolimus-eluting balloons, and also new eluting technologies will further improve the efficacy and the results of peripheral angioplasty. In the next years we will experience the routinary use of new techniques currently under study. In this review, we will discuss the role of drug-coated balloons in the treatment of PAD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425247.2025.2476043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis.
J Soc Cardiovasc Angiogr Interv
January 2025
Yale Cardiovascular Research Group, Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Background: To understand the relative safety and efficacy of endovascular treatment modalities used for superficial femoral artery (SFA) disease, we performed a network meta-analysis to compare outcomes between percutaneous transluminal angioplasty (PTA), atherectomy (A), bare metal stent (BMS), brachytherapy/radiotherapy, covered stent graft (CSG), cutting balloon angioplasty (CBA), drug-coated balloon (DCB), drug-eluting stent (DES), and intravascular lithotripsy (L).
Methods: We performed a systematic literature search of PubMed from January 2000 to January 2023 to identify randomized trials comparing endovascular interventions for the treatment of SFA disease. The primary end points were technical success and 12-month primary patency.
Age-related ten-year outcomes after percutaneous coronary intervention of in-stent restenosis.
Int J Cardiol
March 2025
Deutsches Herzzentrum München, Department of Cardiology, Universitätsklinikum der Technischen Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance, Munich, Germany. Electronic address:
Background: Older patients are often underrepresented in clinical trials investigating the treatment of coronary drug-eluting stent (DES) restenosis, but outcome data is urgently needed in an ageing society. Thus, the aim of this observational, retrospective study was to close this lack of evidence.
Methods: Between January 2007 and February 2021, 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany.
Multistaged Hybrid Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction With Multivessel Disease.
JACC Case Rep
March 2025
Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain. Electronic address:
This paper presents a case of acute myocardial infarction in a patient with a thrombotic occlusion of a diffusely diseased left anterior descending artery, who also had nonculprit severe lesions in the obtuse marginal and right coronary arteries. Considering the extent of the disease and the clinical presentation, a carefully planned multistaged hybrid approach involving drug-eluting balloons and stents was chosen as the optimal revascularization strategy for this patient.
View Article and Find Full Text PDFCurrent insights into drug-coated balloons for peripheral arterial disease.
Expert Opin Drug Deliv
March 2025
Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Introduction: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. It is often associated with coronary and/or cerebral vascular involvement, leading to a higher risk of cardiovascular and cerebrovascular events, among which myocardial infarction, stroke and death. Cardiovascular prevention has proven effective in reducing the progression of the disease and early diagnosis leads to more rapid initiation of medical therapy.
View Article and Find Full Text PDFVascular Response, Downstream Effect, and Pharmacokinetics After Sirolimus- and Paclitaxel-Coated Balloons in Porcine Coronary Arteries.
Catheter Cardiovasc Interv
March 2025
CVPath Institute, Gaithersburg, MD, USA.
Background: Paclitaxel (PCB) and sirolimus-coated balloons (SCB) are major therapeutic options for coronary artery disease, but there is no direct head-to-head histological comparison of their effects during the percutaneous coronary intervention (PCI).
Aims: We aimed to investigate the vascular and downstream effects and drug pharmacokinetics in a porcine coronary model treated with MagicTouch-SCB (MT-SCB), Selution-SRL-SCB (SEL-SCB), Agent PCB, and plain old balloon angioplasty (POBA).
Methods: Twenty-eight coronary arteries from 10 pigs were treated with one of three drug-coated balloons (DCBs) (n = 7 for each) or POBA (n = 7) with 28 days follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!